In conclusion, genetic ablation of Elovl1 combined with anti-PD-1 treatment improves CD8+ T cell activation and functionality in the immune-suppressive microenvironment of pancreatic cancer. Here, PDCD1 is linked to familial pancreatic carcinoma.